NSC 617145

NSC 617145 is a selective werner syndrome helicase (WRN) helicase inhibitor with an IC50 value of 230 nM. NSC 617145 inhibits WRN ATPase, and induces double-strand breaks (DSB) and chromosomal abnormalities. NSC 617145 shows selective for WRN over BLM, FANCJ, ChlR1, RecQ, and UvrD helicases[1].

Product Specifications

CAS Number

[203115-63-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nsc-617145.html

Concentration

10mM

Purity

99.53

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C(Cl)=C(Cl)C1=O)N1CC(C)(C)CN2C(C(Cl)=C(Cl)C2=O)=O

Molecular Formula

C13H10Cl4N2O4

Molecular Weight

400.04

Precautions

H302, H315, H319, H335

References & Citations

[1]Monika Aggarwal, et al. Werner syndrome helicase has a critical role in DNA damage responses in the absence of a functional fanconi anemia pathway. Cancer Res. 2013 Sep 1;73 (17) :5497-507.|[2]R Moles, et al. WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells. J Hematol Oncol. 2016 Nov 9;9 (1) :121.